PT - JOURNAL ARTICLE AU - Feng, Anyin AU - Obolski, Uri AU - Stone, Lewi AU - He, Daihai TI - Modelling COVID-19 Vaccine Breakthrough Infections in Highly Vaccinated Israel – the effects of waning immunity and third vaccination dose AID - 10.1101/2022.01.08.22268950 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.08.22268950 4099 - http://medrxiv.org/content/early/2022/01/10/2022.01.08.22268950.short 4100 - http://medrxiv.org/content/early/2022/01/10/2022.01.08.22268950.full AB - In August 2021, a major wave of the SARS-CoV-2 Delta variant erupted in the highly vaccinated population of Israel. The Delta variant has a transmission advantage over the Alpha variant, and thus replaced it in approximately two months. The outbreak led to an unexpectedly large proportion of breakthrough infections (BTI)-- a phenomenon that received worldwide attention. The BTI proportion amongst cases in the age group of 60+ years reached levels as high as ∼85% in August 2021. Most of the Israeli population, especially those 60+ age, received their second dose of the vaccination, four months before the invasion of the Delta variant. Hence, either the vaccine induced immunity dropped significantly or the Delta variant possesses immunity escaping abilities. In this work, we analyzed and model age-structured cases, vaccination coverage, and vaccine BTI data obtained from the Israeli Ministry of Health, to help understand the epidemiological factors involved in the outbreak. We propose a mathematical model which captures a multitude of factors, including age structure, the time varying vaccine efficacy, time varying transmission rate, BTIs, reduced susceptibility and infectivity of vaccinated individuals, protection duration of the vaccine induced immunity, and the vaccine distribution. We fitted our model to the cases among vaccinated and unvaccinated, for <60 and 60+ age groups, to address the aforementioned factors. We found that the transmission rate was driven by multiple factors including the invasion of Delta variant and the mitigation measures. Through a model reconstruction of the reproductive number R0(t), it was found that the peak transmission rate of the Delta variant was 1.96 times larger than the previous Alpha variant. The model estimated that the vaccine efficacy dropped significantly from >90% to ∼40% over 6 months, and that the immunity protection duration has a peaked Gamma distribution (rather than exponential). We further performed model simulations quantifying the important role of the third vaccination booster dose in reducing the levels of breakthrough infections. This allowed us to explore “what if” scenarios should the booster not have been rolled out. Application of this framework upon invasion of new pathogens, or variants of concern, can help elucidate important factors in the outbreak dynamics and highlight potential routes of action to mitigate their spread.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available human data, which can be obtained from: the Israel Ministry of Health (MOH) and from the World Health Organization (WHO) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. All data produced in the present work are contained in the manuscript. All data produced are available online at the websites of Israel Ministry of Health (MOH) and the World Health Organization (WHO). https://data.gov.il/dataset/covid-19/resource/89f61e3a-4866-4bbf-bcc1-9734e5fee58e?inner_span=True https://data.gov.il/dataset/covid-19/resource/e4bf0ab8-ec88-4f9b-8669-f2cc78273edd?inner_span=True https://data.gov.il/dataset/covid-19/resource/57410611-936c-49a6-ac3c-838171055b1f?inner_span=True https://datadashboard.health.gov.il/COVID-19/general?tileName=SeriousVaccinationStatusDaily https://ourworldindata.org/grapher/covid-variants-area?country=~ISR